Orthocell Posts Strongest US Remplir Sales Month Since Launch
OCC: $0.570 +3.64% · MC: $155M
Orthocell sold 92 units of its Remplir nerve repair product in the US in October, generating $279,000 in revenue. Unit sales rose 84% from the monthly average in the first quarter of FY27. The company attributed the result to growing surgeon adoption, repeat use, a broader distributor network and expanded hospital access.

Comments